2018 Year In Review: Securities Litigation Against Life Sciences and Healthcare Companies

Over the past several years, there has been a substantial increase in the number of class actions and other securities litigation filed against publicly traded life sciences, pharmaceutical, medical device, biotech, health care product and service companies and that trend has continued in 2018. In 2018, significant decisions have been issued by federal district courts and courts of appeal across the country, including in the First and Ninth Circuits. In this webinar, we will discuss the data and trends for securities litigation case filings, decisions, and settlements in 2018 and discuss some of the more significant and interesting decisions of 2018 in these jurisdictions, providing in-depth analysis of the potential implications of these decisions, and discussing practical steps you can take to make informed choices related to your business, including your public disclosures.

Goodwin partners Caroline Bullerjahn and Adam Slutsky will be speakers, joined by John Gould of Cornerstone Research.

For registration information, please click here.